With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to Glob­al Blood Ther­a­peu­tics

Stand­ing by a small mol­e­cule ap­proach in sick­le cell dis­ease even as gene ther­a­py and gene edit­ing play­ers tout land­mark break­throughs, Glob­al Blood Ther­a­peu­tics has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER